PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

Company Previously Announced Planned CEO Transition Following Retirement of Amir Weisberg

PETACH TIKVA, Israel, July 05, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that Dikla Czaczkes Akselbrad, formerly the Company’s Executive Vice President and Chief Financial Officer, has assumed the role of PolyPid’s Chief Executive Officer, effective July 1, 2022. Ms. Czaczkes Akselbrad’s appointment was announced in January 2022, and follows the retirement of Amir Weisberg, who served as the Company’s CEO since 2010, and led PolyPid through its development phase.

“I am looking forward to PolyPid continuing to flourish under Dikla’s leadership,” said Jacob Harel, chairman of PolyPid’s board of directors. “Dikla’s strong industry background and proven ability to guide the Company’s strategic, operational and financial objectives over the past eight years make her an excellent fit for this role. Her expertise in driving growth and innovation will be instrumental as PolyPid prepares for a potential New Drug Application submission and the commercialization of D-PLEX100.”

Ms. Czaczkes Akselbrad joined PolyPid as Chief Strategy Officer in 2014 and has served as PolyPid’s Executive Vice President and Chief Financial Officer since 2017, leading the Company’s initial public offering on the Nasdaq Global Market in June 2020. Ms. Czaczkes Akselbrad has over 20 years of experience in leading life sciences companies through critical international strategic, financial and business transitions, including raising over $350 million in various forms in her prior two CFO roles, including at Compugen Ltd. (Nasdaq & TLV: CGEN).

“I am honored to serve as the CEO of PolyPid, a company committed to improving clinical outcomes for patients,” said Ms. Czaczkes Akselbrad. “I would like to recognize the tremendous effort by the talented PolyPid team, especially in making key accomplishments in our clinical development and manufacturing areas over the past several years, and bringing us to the cusp of important events for the Company, including the anticipated results of our pivotal Phase 3 trial.”

PolyPid recently announced the completion of its SHIELD I Phase 3 study of D-PLEX100 for the prevention of surgical site infections in abdominal surgery, with top-line results expected by end of the current quarter.